ASCO 2026 preview – recent wins come under the spotlight
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
AACR 2026 – Moderna touts first-line data
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
AACR 2026 – Matisse paints a mixed picture for Innate
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ASCO 2026 preview – Revolution completes its rout
Daraxonrasib scores a plenary session late-breaker.
AACR 2026 – Qilu challenges Torl in Claudin6
The company’s conjugate QLS5132 has produced intriguing, but early results.
AACR 2026 – Circle’s focus narrows
First-in-human results prompt a biomarker-defined approach for CID-078.
SGO 2026 – GSK bucks the B7-H4 trend
The group impresses in ovarian and endometrial cancers.
AACR 2026 – private biotechs score plenaries
Circle Pharma and Verismo feature in coveted sessions.
